Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells 9,102 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,102 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the sale, the chief executive officer now directly owns 115,920 shares in the company, valued at approximately $5,589,662.40. This trade represents a 7.28 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $47.92, for a total transaction of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM opened at $51.23 on Friday. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The firm’s 50 day moving average is $44.61 and its 200-day moving average is $42.17. Mirum Pharmaceuticals, Inc. has a 12-month low of $23.14 and a 12-month high of $53.49. The stock has a market capitalization of $2.46 billion, a P/E ratio of -25.36 and a beta of 0.96.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.15. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The business had revenue of $90.38 million during the quarter, compared to analyst estimates of $81.99 million. During the same period last year, the company posted ($0.57) EPS. The company’s revenue was up 89.4% compared to the same quarter last year. Equities research analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MIRM has been the subject of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Citigroup increased their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners lifted their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Robert W. Baird upped their price objective on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $57.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jones Financial Companies Lllp lifted its position in shares of Mirum Pharmaceuticals by 100.0% in the 4th quarter. Jones Financial Companies Lllp now owns 714 shares of the company’s stock valued at $30,000 after acquiring an additional 357 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after purchasing an additional 318 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter worth $69,000. Avanza Fonder AB purchased a new position in shares of Mirum Pharmaceuticals during the fourth quarter valued at $189,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in Mirum Pharmaceuticals during the third quarter valued at $215,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.